Siegfried Holding AG (SWX:SFZN) signed a binding agreement to acquire Two Pharmaceutical Manufacturing Sites of Novartis AG from Novartis AG (SWX:NOVN) on September 29, 2020. Financing of the transaction is secured by existing credit facilities. The transaction is subject to approval by regulatory board/committee and customary closing. The transaction is expected to close at the end of 2020. Following completion of the transaction, Siegfried Holding AG intends to issue hybrid convertible bonds for refinancing. As of October 5, 2020, EGS Beteiligungen AG is participating in the financing by subscribing to two hybrid convertible bonds from Siegfried Holding for a total of CHF 80 million. Mariano Ucar and Juan Carlos Hernanz of Cuatrecasas, Gonçalves Pereira, S.L.P. and Homburger AG acted as legal advisor to Siegfried Holding AG. PharmaVentures Ltd. acted as a financial advisor to Novartis AG (SWX:NOVN). Ernst & Young AG acted as due diligence provider to Siegfried Holding AG (SWX:SFZN). Ernst & Young SA acted as financial advisor to Siegfried Holding AG.

Siegfried Holding AG (SWX:SFZN) completed the acquisition of Two Pharmaceutical Manufacturing Sites of Novartis AG from Novartis AG (SWX:NOVN) on January 1, 2021.